Vice-president of research and development (R&D) Dr Trevor Calkins discusses Pfanstiehl’s active pharmaceutical ingredients (API) contract development and manufacturing organisation (CDMO) philosophy and capabilities at the CPhI/InformEx exhibition in Philadelphia.

Pfanstiehl offers a wide array of API development services at its campus just north of Chicago.
  The company has one of the first Safebridge-certified facilities in the world and is passionate about solving complex chemistry challenges.
The company is focused on being in lockstep with clients from early preclinical through commercialisation.